Antipsychotics and metabolic abnormalities in children and adolescents: A review of the literature and some recommendations;Antipsychotica en metabole afwijkingen bij kinderen en adolescenten; een literatuuroverzicht en aanbevelingen voor de praktijk

Tijdschrift voor Psychiatrie

Volumn 52, Issue 5, 2010, Pages 311-320

  Overbeek, W A ^a   De Vroede, M A M ^b   Lahuis, B E ^c   Hillegers, M H J ^a   De Graeff Meeder, E R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Kinder en Jeugdpsychiatrie te Ede ^*  (Netherlands)

Author keywords

Adolescents; Antipsychotics; Children; Diabetes mellitus type 2; Metabolic syndrome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; BIPOLAR DISORDER; CHILD; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; GROUPS BY AGE; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; RISK ASSESSMENT; WEIGHT GAIN;

EID: 77952736461     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Alvarez-Jiménez, M., González-Blanch, C., Crespo-Facorro, B., e.a. (2008). Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs, 22, 547-562.
2. American Diabetes Association, American Psychiatry Association, American Association of Clinical Endocrinologists, e.a. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. The Journal of Clinical Psychiatry, 65, 267-272.
3. Ashwell, M., Cole, T.J., & Dixon, A.K. (1996). Ratio of waist circumference to height is strong predictor of intra-abdominal fat. BMJ, 313, 559-560.
4. Bloch, Y., Vardi, O., Mendlovic, S., e.a. (2003). Hyperglycemia from olanzapine treatment in adolescents. Journal of Child and Adolescent Psychopharmacology, 13, 97-102.
5. Brown, S., Birtwistle, J., Roe, L., e.a. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697-701.
6. Cahn, W., Ramlal, D., Bruggeman, R., e.a. (2008). Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschrift voor Psychiatrie, 50, 579-591.
7. CBO Kwaliteitsinstituut voor de Gezondheidszorg (2008). Richtlijn diagnostiek en behandeling van obesitas bij volwassenen en kinderen. http://www.cbo.nl/Downloads/307/rl-obesitas-08.pdf
8. Cohen, D., & Huinink, S. (2007). Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs, 21, 1035-1038.
9. Cole, T.J., Bellizi, M.C., Flegal, K.M., e.a. (2000). Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ, 320, 1-6.
10. Correll, C.U., & Carlson, H.E. (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 771-791.
11. Correll, C.U. (2008). Antipsychotic use in children and dolescents: minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 9-20.
12. Curtin, C., Bandini, L.G., Perrin, E.C., e.a. (2005). Prevalence of overweight in children and adolescents with attention deficit hyperactivity disorder and autism spectrum disorders: a chart review. BMC Pediatrics, 5, 48.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
14. Fedorowicz, V., & Fombonne, E. (2005). Metabolic side effects of atypical antipsychotics in children: a literature review. Journal of Psychopharmacoly, 19, 533-550.
15. Frazier, J.A., Biederman J., Tohen, M., e.a. (2001). A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 11, 239-250.
16. Fredriks, A.M., van Buuren, S., Fekkes, M., e.a. (2005). Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice? European Journal of Pediatrics, 164, 216-222.
17. Hurk, K. van den, van Dommelen, P., de Wilde, J.A., e.a. (2006). Prevalentie van overgewicht en obesitas bij jeugdigen 4-15 jaar in de periode 2002-2004. Leiden: TNO.
18. Jensen, P.S., Buitelaar, J., Pandina, G.J., e.a. (2007). Management of psychiatric disorders in children en adolescents with atypical antipsychotics. European Child and Adolescent Psychiatry, 16, 104-120.
19. Lambert, T.J., & Chapman, L.H. (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. The Medical Journal of Australia, 181, 544-548.
20. Lumeng, J.C. (2008). Overweight and psychiatric illness in children. Southern Medicine, 101, 367-372.
21. Maffeis, C., Banzato, C., & Talamni, G. (2008). Waist-to-height ratio, a useful index to identify high metabolic risk in overweight children. Journal of Pediatrics, 152, 207-213.
22. McCarthy, H.D. (2006). Body fat measurements in children as predictors for the metabolic syndrome: focus on waist circumference. Proceedings of the Nutrition Society, 65, 385-392.
23. Masi, G., Mucci, M., & Pari, C. (2006). Children with schizophrenia; clinical picture and pharmacological treatment. CNS Drugs, 20, 841-866.
24. Patel, N.C., Hariparsad, M., Matias-Akthar, M., e.a. (2007). Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology, 17, 303-311.
25. Reinehr, T., de Sousa, G., Toschke, A.M., e.a. (2007). Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach. Archives of Disease in Childhood, 92, 1067-1072.
26. Research Units on Pediatric Psychopharmacology, Autism Network (RUPP) (2005). Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. The American Journal of Psychiatry, 162, 1361-1369.
27. Risselada, A.J., & Mulder, H. (2008). Genetische beïnvloeding van antipsychotica-geïnduceerde gewichtstoename. Psyfar, 15-21.
28. Rotteveel, J., Belksma, E.J., Renders, C.M., e.a. (2007). Type 2 diabetes in children in the Netherlands: the need for diagnostic protocols. European Journal of Endocrinology, 157, 175-180.
29. Safer, D.J. (2004). A comparison of risperidone-induced weight gain across the age span. Journal of Clinical Psychopharmacology, 24, 429-436.
30. Savva, S.C., Tornaritis, M., & Savva, M.E. (2000). Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index. International Journal of Obesity and Related Metabolic Disorders, 24, 1453-1458.
31. Scheepers-Hoeks, A.M., Wessels-Basten, S.J., Scherders, M.J., e.a. (2008). Schizofrenie en antipsychotica: samenhang met het metabool syndroom. Tijdschrift voor Psychiatrie, 50, 645-654.
32. Steinberger, J., Daniels, S.R., Eckel, R.H., e.a. (2009). Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation, 119, 628-647.
33. Troost, P.W., Lahuis, B.E., Steenhuis, M.S., e.a. (2005). Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 1137-1144.
34. Vieweg, W.V., Kuhnley, L.J., Kuhnley, E.J., e.a., (2005). Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 29, 511-515.
35. Wijnen, L.G.C. van, van Wendel-Vos, G.C.W., Wammes, B.M., e.a. (2009). The impact of school-based prevention of overweight on psychosocial well-being of children. Obesity reviews, 10, 298-312.
36. Woods, S.W., Martin, A., Spector, S.G., e.a. (2002). Effects of development on olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1439-1446.
37. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A Working Group Report from the National High Blood Pressure Education Program National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. (1996). Pediatrics, 98, 649-658.